15
Oct
2024
Designing Protein Drugs for Cancer & Autoimmunity: Chris Garcia on The Long Run
Today’s guest on The Long Run is K. Christopher Garcia. Chris is a professor of molecular and cellular physiology and structural biology at Stanford University and an investigator for the Howard Hughes Medical Institute. To be a bit more specific, you can call him a structural immunologist – the kind of scientist who uses the vivid tools of structural biology... Read More
8
Oct
2024
Call for Entries: Join the Timmerman Traverse for Damon Runyon Cancer Research
Are you ready for a bucket list adventure? Join me and a team of biotech executives and investors on the Timmerman Traverse for Damon Runyon Cancer Research Foundation. It’s a trek to Everest Base Camp (17,600 feet) in April 2025. Who’s on the Team? Luke Timmerman, founder & editor, Timmerman Report (team captain) Soufiane Aboulhouda, co-founder and CEO, Nucleate Tamar... Read More
26
Sep
2024
Boundless Bio Takes on Oncogene Amplified Cancers: Zach Hornby on The Long Run
Zach Hornby is today’s guest on The Long Run. Zach is the CEO of San Diego-based Boundless Bio. The company is seeking to target cancer cells in an unusual way. It is developing small molecule drugs that take aim at DNA that resides outside the usual home on a chromosome. These oncogene amplifications occur in loops outside the chromosome. This... Read More
4
Sep
2024
Arsenal Bio Fetches $325M To Make CAR-T Therapies for Solid Tumors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
May
2024
Delphia Raises $67M to Nudge Cancer Cells Beyond the Red Line
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Mar
2024
Clasp, Backed by Catalio, Third Rock & Novo, Gets $150M for Specific T-cell Engagers
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Feb
2024
CRISPR to Protect the Bone Marrow & Attack Cancer: Robert Ang on The Long Run
Today’s guest on The Long Run is Robert Ang. Robert is the CEO of Cambridge, Mass.-based Vor Bio. The company is working on what I think you could call an elegant application of CRISPR gene editing for the treatment of acute myeloid leukemia. The idea here takes some explaining but is pretty simple. Patients with acute myeloid leukemia typically get... Read More
4
Jan
2024
MOMA Gets Roche Deal, $66M Upfront, to Discover Novel Small Molecule Cancer Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Dec
2023
Give to the Next Generation of Scientists
This is the time of year when many people sit down and think about the causes they want to support. I’m asking you to consider donating today to young scientists through the Damon Runyon Cancer Research Foundation. Why Young Scientists? Our system for funding science doesn’t do enough to support young people. The average age of a first-time NIH grant... Read More
9
Nov
2023
Vor Bio Shows CRISPR’d Stem Cell Transplants Take Hold in AML Patients, Enable ADCs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Nov
2023
ProfoundBio, Challenging ImmunoGen, Delivers Responses in First Clinical Trial
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Oct
2023
Nimbus HPK1 Inhibitor Activates Immune System Against Tumors in Early Clinical Trial
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Jul
2023
Versant-Backed Nexo Gets $60M to Pursue Tough Cancer Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jul
2023
Betting on Bold and Brave Ideas for Cancer: Yung Lie on The Long Run
Today’s guest on The Long Run is Yung Lie. Yung is the president and CEO of the Damon Runyon Cancer Research Foundation. The New York-based foundation supports some of the best young scientists around the US and gives them funds to pursue their bold and brave ideas. To give just one example, it bet on cancer immunotherapy research when it... Read More
10
Jul
2023
Detecting Cancer Early When It’s Most Treatable: Kevin Conroy on The Long Run
Today’s guest on The Long Run is Kevin Conroy. Kevin is the chairman and CEO of Madison, Wis.-based Exact Sciences. Exact Sciences has grown over the past decade into a success story for cancer screening and diagnosis. It’s best known for marketing the noninvasive Cologuard test that screens people for colorectal cancer. It also markets the Oncotype DX test that’s... Read More
23
May
2023
Larkspur Gets $35.5M to Make Small Molecule Cancer Immunotherapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Apr
2023
Function Gets $28M to Make Personalized Cancer Genomics to the Next Level
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Mar
2023
Jan Skvarka, former Trillium CEO, on Driving a Turnaround
Jan Skvarka isn’t a household name in biotech. Maybe he should be. Skvarka was previously the CEO of Trillium Therapeutics, where he led a remarkable turnaround of the Canadian small cap biotech into a leading immune oncology player. Trillium had a market capitalization of $16 million when he started. Over the next two years, he led it to a $2.26... Read More
22
Mar
2023
Flare Therapeutics Gets $123M to Make Drugs Against Elusive Transcription Factors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Feb
2023
Engineered B-Cell Therapies for Cancer & Rare Diseases: Joanne Smith-Farrell on The Long Run
Today’s guest on The Long Run is Joanne Smith-Farrell. Joanne is the CEO of Cambridge, Mass.-based Be Biopharma. Many listeners of this show are familiar with the explosion of activity in cell therapy. Engineered T cell therapies have delivered extraordinary results for people with certain types of cancer. The success in these personalized T cell therapies, which get modified outside... Read More